The record
| Class | bioregulator |
|---|---|
| Also known as | KEDP, Lys-Glu-Asp-Pro, prostate tetrapeptide |
| Chain length | 4 residues |
| Molecular weight | 488.54 Da |
| Half-life | - |
| Route | SC / oral (class) |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | Khavinson tetrapeptide bioregulator for prostate tissue; studied for prostate cell proliferation and anti-inflammatory effects in chronic prostatitis models. |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- GI Inflammation Modulation (affection, 36%)
- Inflammation Modulation (affection, 38%)
- Cancer immunotherapy adjuvant (illness, 30%)
- COVID-19 (illness, 30%)
- Hepatitis B/C treatment (illness, 30%)
- Sepsis treatment (illness, 30%)
- Vaccine adjuvant (illness, 30%)
- Pain (symptom, 50%)
- Frequent infections (symptom, 50%)